Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 14:
15. The Ligand Drug Conjugate compound of claim 6 wherein the compound is represented by the structure of:, or pharmaceutically acceptable salt(s) thereof, wherein
subscript a is 1, so that A is present, wherein A is an alpha-amino, beta-amino or another amine-containing acid residue;
Ra3 is —H, C1-C6 alkyl, —C1-C4 alkylene-(C6-C10 aryl), or RPEG1—O—(CH2CH2O)n′—RPEG2 wherein RPEG1 is C1-C4 alkylene, RPEG2 is —H or C1-C4 alkyl, and subscript n′ ranges from 1 to 36, wherein the basic nitrogen atom bonded to Ra3 is optionally protonated;
R′ is hydrogen or —NO2;
R45 is —CH2OH or —CO2H;
—N(Ry)D′ represents D, wherein D′ is the remainder of D, and wherein the dotted line indicates optional cyclization of Ry to D′, wherein Ry is hydrogen or optionally substituted C1-C6 alkyl in absence of cyclization to D′ or Ry is optionally substituted C1-C6 alkylene when cyclized to D′;
wherein —O′— represents the oxygen heteroatom of an O-glycosidic bond cleavable by a glycosidase, wherein said cleavage within a Ligand Drug Conjugate initiates release of D as a primary or secondary amine-containing tubulysin or auristatin from that Ligand Drug Conjugate compound,, or
wherein the compound is represented by:, or pharmaceutically acceptable salt(s) thereof, wherein
subscript a is 1, so that A is present, wherein A is an alpha-amino, beta-amino or another amine-containing acid residue;
Ra3 is —H, C1-C6 alkyl, —C1-C4 alkylene-(C6-C10 aryl), or —RPEG1—O—(CH2CH2O)n′—RPEG2, wherein RPEG1 is C1-C4 alkylene, RPEG2 is —H or C1-C4 alkyl, and subscript n′ ranges from 1 to 36, wherein the basic nitrogen atom bonded to Ra3 is optionally protonated;
R34 is methyl or isopropyl;
R35 is methyl, —(CH2)4—NH2, —(CH2)3NH(C═O)NH2, —(CH2)3NH(C═NH)NH2, or, —(CH2)2CO2H;
—N(Ry)D′ represents -D having covalent attachment to the remainder of the compound structure, wherein D′ is the remainder of D, and wherein the dotted line indicates optional cyclization of Ry to D′, wherein Ry is hydrogen or optionally substituted C1-C6 alkyl in absence of cyclization to D′, or Ry is optionally substituted C1-C6 alkylene when cyclized to D′; and
wherein protease cleavage of the indicated bond within a Ligand Drug Conjugate initiates release of D as a primary or secondary amine-containing tubulysin or auristatin from that Ligand Drug Conjugate compound.